GNI Group (2160) · InitiativeAdvanced
Transition of Eisai’s direct-sales structure
First written in FY2016-Q3. 2 of 3 entries say "Advanced", first in FY2017. Latest entry: FY2019.
3entries
5years
0from disclosures
How it moved
Same theme, other companies
Transition to a Direct-Sales Organization for the Pirfenidone Product アイ スーリュイA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2019AdvancedAnnual report
「医薬品事業の使用人数が前連結会計年度と比べて116名増加しましたのは、当連結会計年度において、人員（主に営業人員）を増強したためです。」
医薬品事業の人員、主に営業人員を116名増強し、連結人員が458名となった。 - FY2017AdvancedAnnual report
「従業員数が前連結会計年度末に比べ92名増加しましたのは、2017年７月31日付でBerkeley Advanced Biomaterials LLCを連結子会社化したためと、当連結会計年度において、医薬品事業の営業人員を増強したためです。」
医薬品事業の営業人員を増強し、連結従業員数が前年末比92名増加した。 - FY2016-Q3First statedAnnual report
「During the three-month period ended the third quarter, we transitioned Etuary’s sales activities from a structure using distributors to a direct sales structure operated by a dedicated in-house sales team.」
The company moved from a distributor-based sales structure to direct sales through its dedicated in-house sales team, with the aim of improving revenue growth, margins, and the quality of services provided to patients and physicians.